Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.49 |
| ▸ | IDO1 | P14902 | 5/20 | 0.49 |
| ▸ | PNMT | P11086 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | PTPRG | P23470 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9976779 | 0.93 | IDO1 (0.46) | TAAR1IDO1PNMTTP53MAPT | |
| SCHEMBL2803352 | 0.88 | IDO1 (0.58) | TAAR1IDO1PNMTCYP3A4AGXT | |
| SCHEMBL2804525 | 0.88 | TAAR1 (0.58) | TAAR1IDO1MAPTLMNACYP3A4 | |
| SCHEMBL26049437 | 0.85 | IDO1 (0.51) | TAAR1IDO1PNMTPOLBCYP3A4 | |
| SCHEMBL14685891 | 0.82 | TAAR1 (0.53) | TAAR1IDO1PNMTTP53MAPT | |
| SCHEMBL18773953 | 0.82 | TAAR1 (0.59) | TAAR1PNMTAOC3 | |
| SCHEMBL9976793 | 0.80 | IDO1 (0.55) | TAAR1IDO1PNMTCYP3A4AGXT | |
| SCHEMBL9976772 | 0.80 | TAAR1 (0.55) | TAAR1IDO1MAPTLMNACYP3A4 | |
| SCHEMBL4267674 | 0.80 | TAAR1 (0.55) | TAAR1IDO1MAPTLMNACYP3A4 | |
| SCHEMBL26049509 | 0.80 | IDO1 (0.47) | TAAR1IDO1PNMTCYP3A4AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202997-B2 | Compositions and methods for treating or preventing hypoxic or ischemic injury | IKARIA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100130555-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | IKARIA, INC. (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130555-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPOXIC OR ISCHEMIC INJURY | HIF1AN, HIF1A, HYOU1 | TAAR1 3367/4885IDO1 935/4885PNMT 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.